- Author: Raed A Dweik, MD, FACP, FRCPC, FCCP, FCCM, FAHA; Chief Editor: Zab Mosenifar, MD, FACP, FCCP more...
Further Outpatient Care
Chronic beryllium disease (CBD, berylliosis) patients should be monitored by a pulmonologist. The frequency of follow-up depends on the extent of the disease and the need for therapy.
Prevention is a key component in the management of CBD.
The current OSHA standards for workplace air require an 8-hour, time-weighted average maximum permissible level of 2 mcg/m3, along with a peak level of 25 mcg/m3. The beryllium concentration in the air around factories is not to exceed 0.01 mcg/m3. Some recent studies suggest that the current standard of 2 mcg/m3 is not protective.
Although no proof exists that cessation of exposure to beryllium improves the disease course or slows the progression, advising all patients with CBD to avoid any further exposure to beryllium is prudent.
Monitor for complications of corticosteroid therapy in patients receiving such therapy.
The natural history of CBD remains unclear. While many patients are asymptomatic at the time of diagnosis and may remain so, some patients experience progressive decline in their lung function that may progress to respiratory failure requiring oxygen supplementation and, in certain advanced cases, lung transplantation.
Certain individuals with beryllium sensitization or chronic beryllium disease may be eligible for government benefits and compensation under the Energy Employees Occupational Illness Compensation Program. More information is available on the US Department of Labor Web site, Division of Energy Employees Occupational Illness Compensation.
For excellent patient education resources, see eMedicineHealth's patient education article Bronchoscopy.
Saltini C, Winestock K, Kirby M, Pinkston P, Crystal RG. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med. 1989 Apr 27. 320(17):1103-9. [Medline].
Van Dyke MV, Martyny JW, Mroz MM, et al. Risk of Chronic Beryllium Disease by HLA-DPB1 E69 Genotype and Beryllium Exposure in Nuclear Workers. Am J Respir Crit Care Med. 2011 Mar 11. [Medline].
Harber P, Su J, Alongi G. Exposure factors associated with chronic beryllium disease development in Beryllium BioBank participants. J Occup Environ Med. 2014 Aug. 56 (8):852-6. [Medline].
Berlin JM, Taylor JS, Sigel JE, Bergfeld WF, Dweik RA. Beryllium dermatitis. J Am Acad Dermatol. 2003 Nov. 49(5):939-41. [Medline].
Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science. 1993 Oct 8. 262(5131):242-4. [Medline].
Barna BP, Culver DA, Yen-Lieberman B, Dweik RA, Thomassen MJ. Clinical application of beryllium lymphocyte proliferation testing. Clin Diagn Lab Immunol. 2003 Nov. 10(6):990-4. [Medline].
Newman LS. Significance of the blood beryllium lymphocyte proliferation test. Environ Health Perspect. 1996 Oct. 104 Suppl 5:953-6. [Medline].
Rossman MD, Kern JA, Elias JA, Cullen MR, Epstein PE, Preuss OP, et al. Proliferative response of bronchoalveolar lymphocytes to beryllium. A test for chronic beryllium disease. Ann Intern Med. 1988 May. 108(5):687-93. [Medline].
Balmes JR, Abraham JL, Dweik RA, Fireman E, Fontenot AP, Maier LA, et al. An official American Thoracic Society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease. Am J Respir Crit Care Med. 2014 Nov 15. 190 (10):e34-59. [Medline].
Harber P, Su J. Beryllium Biobank 3: considerations for improving chronic beryllium disease screening. J Occup Environ Med. 2014 Aug. 56 (8):861-6. [Medline].
Newman LS, Buschman DL, Newell JD Jr, Lynch DA. Beryllium disease: assessment with CT. Radiology. 1994 Mar. 190(3):835-40. [Medline].
Kreiss K, Mroz MM, Newman LS, Martyny J, Zhen B. Machining risk of beryllium disease and sensitization with median exposures below 2 micrograms/m3. Am J Ind Med. 1996 Jul. 30(1):16-25. [Medline].
Amicosante M, Berretta F, Franchi A, Rogliani P, Dotti C, Losi M, et al. HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells. Eur Respir J. 2002 Nov. 20(5):1174-8. [Medline].
Culver DA, Dweik RA. Chronic beryllium disease. Clin Pulm Med. 2003. 10:72-9.
Kreiss K, Miller F, Newman LS, Ojo-Amaize EA, Rossman MD, Saltini C. Chronic beryllium disease--from the workplace to cellular immunology, molecular immunogenetics, and back. Clin Immunol Immunopathol. 1994 May. 71(2):123-9. [Medline].
Kreiss K, Mroz MM, Zhen B, Wiedemann H, Barna B. Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup Environ Med. 1997 Aug. 54(8):605-12. [Medline].
Kreiss K, Newman LS, Mroz MM, Campbell PA. Screening blood test identifies subclinical beryllium disease. J Occup Med. 1989 Jul. 31(7):603-8. [Medline].
Kriebel D, Brain JD, Sprince NL, Kazemi H. The pulmonary toxicity of beryllium. Am Rev Respir Dis. 1988 Feb. 137(2):464-73. [Medline].
Meyer KC. Beryllium and lung disease. Chest. 1994 Sep. 106(3):942-6. [Medline].
MOSBY'S GENRx-The Complete Reference For Generic And Brand Drugs. 9th ed. St. Louis, Mo: Mosby-Year Book; 1999.
Müller-Quernheim J, Gaede KI, Fireman E, Zissel G. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. Eur Respir J. 2006 Jun. 27(6):1190-5. [Medline].
Newman LS. Immunology, genetics, and epidemiology of beryllium disease. Chest. 1996 Mar. 109(3 Suppl):40S-43S. [Medline].
Newman LS, Kreiss K, King TE Jr, Seay S, Campbell PA. Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am Rev Respir Dis. 1989 Jun. 139(6):1479-86. [Medline].
Newman LS, Lloyd J, Daniloff E. The natural history of beryllium sensitization and chronic beryllium disease. Environ Health Perspect. 1996 Oct. 104 Suppl 5:937-43. [Medline].
Newman LS, Mroz MM, Balkissoon R, Maier LA. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med. 2005 Jan 1. 171(1):54-60. [Medline].
Pappas GP, Newman LS. Early pulmonary physiologic abnormalities in beryllium disease. Am Rev Respir Dis. 1993 Sep. 148(3):661-6. [Medline].
Saber W, Dweik RA. A 65-year-old factory worker with dyspnea on exertion and a normal chest x-ray. Cleve Clin J Med. 2000 Nov. 67(11):791-2, 794, 797-8, 800. [Medline].
Stokes RF, Rossman MD. Blood cell proliferation response to beryllium: analysis by receiver-operating characteristics. J Occup Med. 1991 Jan. 33(1):23-8. [Medline].